September 23, 2017 11:51 PM ET


Company Overview of Celator Pharmaceuticals, Inc.

Company Overview

Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company’s product pipeline includes VYXEOS, a nano-scale liposomal formulation of irinotecan:floxuridine, which is in Phase III clinical testing for the treatment of acute myeloid leukemia; CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and ...

200 PrincetonSouth Corporate Center

Suite 180

Ewing, NJ 08628

United States

Founded in 1999

25 Employees



Key Executives for Celator Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 52
Founder, President and Chief Scientific Officer
Age: 61
Executive Chairman
Age: 59
Chief Financial Officer and Vice President
Age: 56
Chief Medical Officer
Compensation as of Fiscal Year 2017.

Celator Pharmaceuticals, Inc. Key Developments

Celator Pharmaceuticals, Inc. Presents at BIO International Conference 2017, Jun-21-2017 01:45 PM

Celator Pharmaceuticals, Inc. Presents at BIO International Conference 2017, Jun-21-2017 01:45 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Derek Miller, Chief Business Officer.

Celator Pharmaceuticals, Inc. Files Form 15

Celator Pharmaceuticals, Inc. announced that it has filed Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock of par value $0.001 per share under the Securities Exchange Act of 1934, as amended.

Celator Pharmaceuticals, Inc.(NasdaqGM:CPXX) dropped from NASDAQ Composite Index

Celator Pharmaceuticals, Inc. has been removed from Nasdaq Composite Index.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celator Pharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at